Sio Gene Therapies (Sio Gene Therapies) 6-1 Month Momentum %

: -0.80% (As of Today)

View and export this data going back to 2015. Start your Free Trial

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-24), Sio Gene Therapies's 6-1 Month Momentum % is -0.80%.

The industry rank for Sio Gene Therapies's 6-1 Month Momentum % or its related term are showing as below:

SIOX's 6-1 Month Momentum % is not ranked
in the Biotechnology industry.
Industry Median: 2.99 vs SIOX: -0.80

Competitive Comparison

For the Biotechnology subindustry, Sio Gene Therapies's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sio Gene Therapies 6-1 Month Momentum % Distribution

For the Biotechnology industry and Healthcare sector, Sio Gene Therapies's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Sio Gene Therapies's 6-1 Month Momentum % falls into.

Sio Gene Therapies (OTCPK:SIOX) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sio Gene Therapies (OTCPK:SIOX) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Sio Gene Therapies 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Sio Gene Therapies's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sio Gene Therapies (Sio Gene Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sio Gene Therapies Inc (OTCPK:SIOX) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

130 West 42nd Street, 26th Floor, New York, NY, USA, 10036

Website

https://www.siogtx.com

Sio Gene Therapies Inc is a clinical-stage company that is focused on gene therapy for neurodegenerative diseases. The company is developing its pipeline for the treatment of debilitating diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis.

Executives

Parag V Meswani	officer: Chief Commercial Officer	130 WEST 42ND STREET, 26TH FLOOR, NEW YORK NY 10036
Pavan Cheruvu	officer: Chief Executive Officer	C/O AXOVANT SCIENCES, INC., 11 TIMES SQUARE, 33RD FLOOR, NEW YORK NY 10036
Atul Pande	director	C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Kristiina Md Vuori	director	C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
Roivant Sciences Ltd.	10 percent owner	CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Eric Venker	director	C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
David W. Nassif	officer: Principal Financial Officer	C/O STEADYMED THERAPEUTICS, INC., 2410 CAMINO RAMON, SAN RAMON CA 94583
Senthil Vel Sundaram	director	NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Dexxon Holdings Ltd.	10 percent owner	1 DEXCEL STREET, OR AKIVA L3 30600000
Andrew Lo	10 percent owner	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Svf Investments (uk) Ltd	10 percent owner	69 GROSVENOR STREET, LONDON X0 W1K3JP
Patrick Machado	10 percent owner	201 SPEAR STREET, 3RD FLOOR, SAN FRANCISCO CA 94107
Qvt Associates Gp Llc	10 percent owner	1177 AVENUE OF THE AMERICAS, 9TH FLOOR, NEW YORK NY 10036
Viking Global Performance Llc	10 percent owner	55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901